Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, Krogh V, Munnia A, Tumino R, Polidoro S, Piazza A, Vineis P: XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001, 22: 1437–1445.CrossRefPubMed 22. Pachkowski

BF, Winkel S, Kubota Y, Swenberg JA, Millikan RC, Nakamura J: XRCC1 genotype and breast cancer: functional studies and epidemiologic data show interactions between XRCC1 codon 280 His and smoking. Cancer Res 2006, 66: 2860–2868.CrossRefPubMed 23. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy CFTRinh-172 M, Harris CC: Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001, 22: 593–597.CrossRefPubMed 24. Sancar A: Excision repair in mammalian cells. J Biol Chem 1995, 270: 15915–15918.PubMed 25. Benhamou S, Sarasin A: ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am PRT062607 solubility dmso J Epidemiol 2005, 161: 1–14.CrossRefPubMed 26. Qiao Y, Spitz MR, Shen H, Guo Z, Shete S, Hedayati M, Grossman L, Mohrenweiser H, Wei Q: Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002, 23: 295–299.CrossRefPubMed 27. Spitz MR, Wu X, Wang Y, Wang LE,

Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001, 61: 1354–1357.PubMed 28. Au WW, Salama SA, Sierra-Torres CH: Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003, 111: 1843–1850.CrossRefPubMed 29. Au WW, Navasumrit P, Ruchirawat M: Use of Dasatinib ic50 biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health 2004, 207: 301–313.CrossRefPubMed 30. Costa S, Pinto D, Pereira

D, Vasconcelos A, fonso-Lopes C, Osorio T, Lopes C, Medeiros R: Importance of xeroderma pigmentosum group D polymorphisms in susceptibility to ovarian cancer. Cancer Lett 2007, 246: 324–330.CrossRefPubMed 31. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA: XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000, 21: 551–555.CrossRefPubMed 32. Seker H, Butkiewicz D, Bowman ED, Rusin M, Hedayati ADP ribosylation factor M, Grossman L, Harris CC: Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 2001, 61: 7430–7434.PubMed 33. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, Spitz MR: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000, 92: 1764–1772.CrossRefPubMed 34. Benhamou S, Sarasin A: ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis 2002, 17: 463–469.CrossRefPubMed 35. Caggana M, Kilgallen J, Conroy JM, Wiencke JK, Kelsey KT, Miike R, Chen P, Wrensch MR: Associations between ERCC2 polymorphisms and gliomas.